796,626 Shares in Solventum Corporation $SOLV Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon bought 796,626 shares of Solventum valued at approximately $61.5 million, representing a 0.46% stake. Several other institutional investors also increased their holdings.
• Solventum reported strong quarterly results, with EPS of $2.55 versus the $1.91 consensus estimate and revenue of $2.21 billion, up 2.2% year over year.
• The stock opened at $91.59, near its 52-week high, while analyst sentiment remains a “Moderate Buy” with an average price target of $91.64; KeyCorp and Stifel recently raised their targets to $102 and $100, respectively.

Bank of New York Mellon Corp purchased a new stake in Solventum Corporation (NYSE:SOLV - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 796,626 shares of the company's stock, valued at approximately $61,460,000. Bank of New York Mellon Corp owned 0.46% of Solventum as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SOLV. US Bancorp DE boosted its stake in shares of Solventum by 4.6% during the 4th quarter. US Bancorp DE now owns 444,540 shares of the company's stock worth $35,225,000 after purchasing an additional 19,400 shares during the last quarter. Davis Selected Advisers lifted its stake in shares of Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company's stock valued at $492,880,000 after buying an additional 702,461 shares during the period. SG Americas Securities LLC lifted its stake in shares of Solventum by 38.4% during the first quarter. SG Americas Securities LLC now owns 129,663 shares of the company's stock valued at $8,467,000 after buying an additional 35,982 shares during the period. Bank of America Corp DE boosted its position in Solventum by 0.6% during the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company's stock worth $93,561,000 after acquiring an additional 9,083 shares during the last quarter. Finally, Swiss National Bank boosted its position in Solventum by 7.4% during the first quarter. Swiss National Bank now owns 458,209 shares of the company's stock worth $29,921,000 after acquiring an additional 31,600 shares during the last quarter.

Solventum Trading Down 0.0%

NYSE SOLV opened at $91.59 on Thursday. The firm has a market capitalization of $15.59 billion, a price-to-earnings ratio of 11.20, a PEG ratio of 1.18 and a beta of 0.60. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum Corporation has a one year low of $62.38 and a one year high of $92.71. The company's 50 day moving average price is $81.85 and its 200 day moving average price is $75.35.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the prior year, the business earned $1.69 earnings per share. The business's quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, sell-side analysts predict that Solventum Corporation will post 7.22 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on SOLV. Wells Fargo & Company decreased their price objective on Solventum from $83.00 to $70.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 6th. Weiss Ratings upgraded Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. Wall Street Zen lowered Solventum from a "buy" rating to a "hold" rating in a research note on Saturday, August 22nd. KeyCorp increased their price objective on shares of Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Stifel Nicolaus boosted their target price on shares of Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $91.64.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source